Own CSL (ASX:CSL) shares? Here's why the company is moving on from COVID research

Coronavirus variants are proving resilient against a range of vaccines.

| More on:
gloved hand holding covid-19 vaccine against backdrop of australian flag

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Limited (ASX: CSL) shares are joining the broader ASX selloff today, down 3.93% to $248.20 per share.

The S&P/ASX 200 Index (ASX: XJO) is falling hard too, down 1.47% after posting early morning gains of 0.5%.

That's today's CSL share price action.

Now we turn to why CSL is throwing in the towel on its 2-year long research into COVID-19 vaccines.

Why is CSL moving on from COVID research?

CSL has long been involved in formulating novel vaccines against a range of ailments.

When the coronavirus went global in early 2020, CSL turned its sights onto beating the virus that stemmed from Wuhan, China.

In a partial success story, the biopharmaceutical company manufactured AstraZeneca under license for Australia distribution in Melbourne. Following the reports that AstraZeneca could lead to blood clots in certain rare cases, primarily among younger people, the vaccine was eventually rebranded as Vaxzevria.

However, CSL's efforts at creating its own COVID vaccine eventually failed. The trial vaccine created together with researchers at the University of Queensland had promising results. But the drug was pulled after revelations that it could lead to false positive tests for HIV.

CSL also was part of a larger group of global companies working on a hyperimmune therapy in 2020. That project was ditched after it failed to meet expectations.

Now, as The Australian reports, "CSL … has quietly pulled the plug on developing Covid-19 antiviral treatments as it steams ahead on other projects in its $1bn-a-year research program."

According to a CSL spokesman, "CSL is proud of the role we have played in bringing the Vaxzevria vaccine to millions of Australians, as well as neighbouring countries. At present we are not investigating any antiviral treatments for Covid-19."

But that doesn't spell the end of the company's $1 billion annual research program.

In December, CSL chairman Brian McNamee said (quoted by The Australian):

We are firmly committed to advancing our next-generation sa-mRNA vaccine technology which aims to address some of the challenges presented by the current technology. We will utilise our global network, including research facilities in Cambridge, Massachusetts and clinical scale manufacturing facilities in Holly Springs, North Carolina, to achieve this.

How have CSL shares been performing?

CSL shares have been on a bit of a rollercoaster over the past 12 months, leaving them down 10%. By comparison the ASX 200 is relatively flat since this time last year.

So far in 2022, CSL shares have fallen 15%.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Vanadium Resources share price person riding rocket indicating share price increase
Healthcare Shares

Why did this ASX biotech stock explode 52% higher on Monday?

Shareholders of this stock were smiling today. What happened?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why is everyone talking about ResMed shares?

It’s been a good year for ResMed shareholders. Let’s find out why.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

This bombshell for ASX healthcare shares could hit 6 million Australians

This could have a large impact.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

2 ASX healthcare shares having a stellar run today

The ASX healthcare sector is down today but these two stocks are bucking the trend.

Read more »

A company manager presents the ASX company earnings report to shareholders at an AGM.
Healthcare Shares

Why this $13 billion ASX 200 healthcare stock is surging today

A change in sentiment for the healthcare player.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX 200 stock hit a 52-week low and a top broker thinks it can rebound

Patient investors may see this stock make a pleasing recovery.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Why this sold-off ASX healthcare share could be an exciting dividend buy

This could be a healthy stock for dividends.

Read more »

a smiling woman sits at her computer at home with a coffee alongside her, as if pleased with her investments.
Healthcare Shares

Is CSL the best ASX 100 share to buy now?

Bell Potter has good things to say about this blue chip star.

Read more »